Physician profile
Raphael Nach
NPI 1851497713
$586.99
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $93.82 · 2021: $104 · 2022: $21.38.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $254.70 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $122.10 | 2019 | |
| Aerin Medical INC. | $48.37 | 2019 | |
| Phadia US INC. | $34.45 | 2019 | |
| Stryker Corporation | $21.05 | 2019 | |
| Vyne Pharmaceuticals INC. | $20.16 | 2021 | |
| Intersect Ent, INC. | $18.41 | 2020 | |
| Genentech USA, INC. | $15.27 | 2019 | |
| Tactile Systems Technology INC | $14.23 | 2020 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Epi Health, LLC | $12.65 | 2019 | |
| Celgene Corporation | $12.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Nach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.